ESSA Pharma Inc. Reports Results of Annual General Meeting of Shareholders

On June 25, 2019 ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI,NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is reported the results of the votes on matters considered at its annual general meeting of shareholders of the Company (the "Shareholders") held on June 25, 2019 in Vancouver, British Columbia, Canada (the "Meeting") (Press release, ESSA, JUN 25, 2019, View Source [SID1234537259]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the Meeting, the Shareholders set the number of directors at seven and re-elected to the board of directors (the "Board"), by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Raymond Andersen, Gary Sollis, Franklin M. Berger, Scott Requadt and Otello Stampacchia to serve in office until the next annual meeting of Shareholders or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:

Nominee

Votes For

% Votes For

Votes Withheld

% Votes Withheld

David R. Parkinson

3,413,685

95.64%

155,625

4.36%

Richard M. Glickman

3,420,645

95.83%

148,665

4.17%

Raymond Andersen

3,413,685

95.64%

155,625

4.36%

Gary Sollis

3,560,520

99.75%

8,789

0.25%

Franklin M. Berger

3,415,107

95.68%

154,202

4.32%

Scott Requadt

3,224,071

90.33%

345,238

9.67%

Otello Stampacchia

3,224,062

90.33%

345,248

9.67%

At the Meeting, the Shareholders also approved the: (i) re-appointed of Davidson & Company LLP, Chartered Professional Accountants, as auditors of the Company; (ii) subject to the closing of the acquisition by the Company of all the issued and outstanding shares of Real Therapeutics plc, as announced in a press release dated May 16, 2019 (the "Realm Acquisition"), an amendment to the Company’s stock option plan; (iii) subject to the closing of the Realm Acquisition, an amendment to the Company’s restricted share unit plan; and (iv) subject to the closing of the Realm Acquisition, the Company’s employee stock purchase plan.